Phil is the VP of Systems Integration at VedaBio and is well known for his major contributions in bioinstrumentation for life sciences, diagnostics, and biodefense. With his unique ability to bridge biology and engineering, he has served in key roles in product development efforts including the Inscripta Onyx platform, 10X Genomics Chromium platform, Bio-Rad Droplet Digital PCR system, Cepheid GeneXpert, and the Northrop Grumman Biohazard Detection System.

He received his Ph.D. in Cell and Molecular Biology from the University at Buffalo. He holds 126 issued U.S. patents and over 40 publications in peer-reviewed journals.

Jorge is the Executive Director of Program Management, Platform, and Technology Development with a track record of success leading cross functional teams and complex interdisciplinary technical efforts. Previously, Jorge was a Senior Director of Technology Development at Inscripta, and Microfluidics Engineer at 10X genomics. Jorge is the co-inventor in over 90 patents and patent applications.

Jorge earned his bachelor’s and M.S. in Chemical Engineering from Washington State University, a doctorate in Chemical and Biomolecular Engineering from Johns Hopkins University, and postdoctoral training at Stanford University.

Sally is the VP of Intellectual Property at VedaBio and has over thirty years of legal experience specializing in crafting comprehensive patent portfolios, drafting and prosecuting patent applications, and devising licensing programs with both academic and commercial partners.

Previously, she was VP of Legal at Inscripta and Partner and Co-Founder of Convergent Law Group LLC. She has particular expertise in emerging technologies, with extensive experience conducting and drafting patent validity opinions, conducting due diligence reviews, monitoring competitor portfolios, and directing litigation proceedings.

Andrea is the Director of Instrument Development at VedaBio, and she specializes in leading hardware and consumable engineering teams from concept through to product launch. Prior to VedaBio, Andrea led engineering and systems integration groups at Inscripta, manufacturing technology at Abcam, and served as Director of Engineering at Firefly BioWorks.

Andrea received her PhD in Biological Engineering from MIT and her BS in Bioengineering at the University of California San Diego.

Kim currently holds the role of Director of Strategy and Corporate Development at VedaBio, where her extensive background in clinical diagnostics is instrumental in guiding strategy and facilitating strategic partnerships. Before joining VedaBio, Kim served as Director of Business Development at MeMed Diagnostics, contributed as the Associate Director of Strategy & Business Development at Sherlock Biosciences, and played a crucial role as the Product Management Assay lead for a broad infectious disease portfolio at QIAGEN.

Kim received her BS in Biology from Boston College.

Maurice Exner, PhD, brings more than two decades of experience in global research and development leadership and strategy to VedaBio.

Prior to joining the team, Maurice served as Chief Scientific Officer at Sherlock Biosciences, and earlier as Vice President of Global R&D at Thermo Fisher Scientific’s Genetic Sciences organization, and Vice President of R&D, Assay Development and Clinical Affairs at Hologic. He also held other R&D leadership roles at Abbott, Focus Diagnostics, and Quest Diagnostics. Dr. Exner has extensive experience in clinical diagnostics and in product development, which has culminated in the launch of multiple IVD products, including over 40 FDA cleared/approved products and 8 instrument platforms.

Maurice is a board certified Diplomate of the American Board of Medical Microbiology, and received his BSc in Microbiology from the University of Regina, and his PhD in Microbiology from the University of British Columbia.

‍

Christine Ginocchio is the Chief Medical and Scientific Officer of VedaBio, and a world-renowned expert in molecular diagnostics and clinical microbiology. She has been the principal investigator for more than 60 industry and pharmaceutical clinical trials that include 21 studies of in vitro diagnostic devices for US Food and Drug Administration (FDA) clearance.

Her recent roles prior to joining VedaBio include Chief, Senior Medical Director, Division of Infectious Disease Diagnostics, Department of Pathology and Laboratory Medicine, Professor of Medicine, Northwell Health, NY, Chief Scientific and Medical Officer at Quotient and Senior VP of Global Medical Affairs at bioMérieux/BioFire. At bioMérieux she was responsible for the oversight of global FilmArray medical affairs activities, the investigator-initiated research program, and medical training.

She has served as an expert consultant for numerous international and national health agencies and remains active in numerous editorial boards and professional societies.

Kristen, as Executive Director of Regulatory and Clinical affairs at VedaBio, brings over 15 years of experience developing and executing highly effective and innovative clinical and regulatory strategies for infectious disease IVDs. Previously, Kristen served as the Head of the Regulatory Science division at QIAGEN, SVP of R&D and Programs at BioMerieux/BioFire Diagnostics, and SVP of Regulatory and Clinical Affairs at BioFire Diagnostics.

Kristen received her BS and MS degrees in Medical Microbiology & Immunology and Bacteriology from the University of Wisconsin, Madison, followed by a PhD in Molecular Microbiology & Immunology from the University of Maryland, Baltimore.

As Senior Director of Program Management, Haleigh brings over 20 years of experience driving multidisciplinary teams to bring transformative diagnostic products to market.

Prior to joining the team, Haleigh served as the VP of Programs at BioMerieux and Senior Director of Program Management at BioFire Diagnostics. Haleigh received her BS degree in Chemistry and holds a PMP certification.

G. Brett Robb is the Senior Scientific Director and Head of CRISPR Science at VedaBio, a strategic R&D leader, and accomplished scientist.

Previously, Brett led Research and Early Development for RNA and Programmable Nucleases at New England Biolabs (NEB). He established and led discovery and early development efforts for CRISPR-Cas nucleases and significantly advanced the RNA product portfolio, contributing to the commercialization of over 25 products and positioning NEB as a key player in the fields. Brett has published over 35 peer-reviewed papers and is a co-inventor of 10 patents.

Originally from Canada, Brett received his BSc in Genetics from the University of Western Ontario, PhD from the Department of Medical Biophysics at the University of Toronto, and postdoctoral training at UMASS Medical School.

Fred is the President and CEO of VedaBio and a Venture Partner at OMX Ventures with extensive experience in the healthcare industry.

He currently serves as an Independent Director on several company Boards and holds an Adjunct Professor position at the University of Toronto. Prior to joining VedaBio, Fred held numerous senior leadership roles at MeMed Diagnostics, Versant Ventures, Northern Biologics (sold), bioMérieux and T2 Biosystems (IPO).

Fred received his PhD in Molecular and Medical Genetics from the University of Toronto, and his BS from McGill University.